Cited 0 times in
Specific immunoglobulin E and immunoglobulin G antibodies to toluene diisocyanate-human serum albumin conjugate: useful markers for predicting long-term prognosis in toluene diisocyanate-induced asthma.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, HS | - |
dc.contributor.author | Lee, SK | - |
dc.contributor.author | Kim, HY | - |
dc.contributor.author | Nahm, DH | - |
dc.contributor.author | Kim, SS | - |
dc.date.accessioned | 2011-07-20T02:05:39Z | - |
dc.date.available | 2011-07-20T02:05:39Z | - |
dc.date.issued | 2002 | - |
dc.identifier.issn | 0954-7894 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/3474 | - |
dc.description.abstract | BACKGROUND: Our previous study reported that more than 50% of toluene diisocyanate (TDI)-induced asthma patients had persistent asthmatic symptoms even after complete avoidance. Although specific IgE (sIgE) has been detected in a portion of patients with TDI-asthma, a recent investigation suggests that the presence of serum specific IgG (sIgG), not sIgE, is more closely associated with positive bronchoprovocation test (BPT) results.
OBJECTIVE: To evaluate the possible role of sIgE and sIgG in predicting long-term prognosis of TDI-asthma. MATERIALS AND METHODS: Forty-one TDI-asthma patients whose diagnosis was confirmed by TDI-BPT, and 20 unexposed healthy controls were enrolled. Both sIgE and sIgG to TDI-human serum albumin (HSA) conjugate were detected by ELISA. All patients with persistent asthmatic symptoms took anti-asthmatic medications during the follow-up period (mean: 67.5 months) and were instructed to avoid exposure to TDI. Airway hyper-responsiveness to methacholine (AHM) was monitored every year during the study period. The patients were classified into three groups according to changing patterns of AHM and asthmatic symptoms as follows: group I, no improvement with persistent asthmatic symptoms (n = 12); group II, partial improvement with persistent asthmatic symptoms (n = 13); group III, in remission (n = 16). RESULTS: Favourable prognosis was associated with a mild degree of AHM at initial diagnosis (P < 0.05). Although there were no significant differences in the prevalence of sIgE antibody to TDI-HSA conjugate among the three groups (P > 0.05), prevalence of sIgG in group I tended to be higher than in group II (0.05 < P < 0.1). However, the levels of sIgG were significantly higher in group I than in group II (P = 0.05), whereas levels of sIgE were significantly higher in group II than in group I (P = 0.014). No significant differences were noted in exposure duration, sex, age, atopic status, and total IgE level among the three groups (P > 0.05). CONCLUSION: This study confirmed that a favourable outcome is related to a mild degree of AHM and to low levels of sIgG to predict persistent asthmatic symptoms, it also suggested that the presence of high serum-specific IgE at initial diagnosis may represent a better prognosis. | - |
dc.language.iso | en | - |
dc.subject.MESH | Asthma | - |
dc.subject.MESH | Biological Markers | - |
dc.subject.MESH | Bronchial Hyperreactivity | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunoglobulin E | - |
dc.subject.MESH | Immunoglobulin G | - |
dc.subject.MESH | Kinetics | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Serum Albumin | - |
dc.subject.MESH | Toluene 2,4-Diisocyanate | - |
dc.title | Specific immunoglobulin E and immunoglobulin G antibodies to toluene diisocyanate-human serum albumin conjugate: useful markers for predicting long-term prognosis in toluene diisocyanate-induced asthma. | - |
dc.type | Article | - |
dc.identifier.pmid | 11972601 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0954-7894&date=2002&volume=32&issue=4&spage=551 | - |
dc.contributor.affiliatedAuthor | 박, 해심 | - |
dc.contributor.affiliatedAuthor | 남, 동호 | - |
dc.type.local | Journal Papers | - |
dc.citation.title | Clinical and experimental allergy | - |
dc.citation.volume | 32 | - |
dc.citation.number | 4 | - |
dc.citation.date | 2002 | - |
dc.citation.startPage | 551 | - |
dc.citation.endPage | 555 | - |
dc.identifier.bibliographicCitation | Clinical and experimental allergy, 32(4). : 551-555, 2002 | - |
dc.identifier.eissn | 1365-2222 | - |
dc.relation.journalid | J009547894 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.